J Breast Cancer.  2020 Jun;23(3):268-278. 10.4048/jbc.2020.23.e33.

Effect of Timing of GonadotropinReleasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer

• Shin JJ
• Choi YM
• Jun JK
• Lee KH
• Kim TY
• Han W
• Im SA

• KMID: 2511781
• DOI: http://doi.org/10.4048/jbc.2020.23.e33

Abstract

Purpose
This study was performed to investigate the effect of the interval between the start of gonadotropin-releasing hormone agonist (GnRHa) and the start of chemotherapy on ovarian protection in patients with breast cancer.
Methods
This was a prospective observational cohort study that included 136 patients with breast cancer below 40 years who received GnRHa during chemotherapy for fertility preservation. Plasma anti-Müllerian hormone (AMH) levels were measured before chemotherapy (baseline) and after chemotherapy. Subjects were divided into 3 groups according to the interval between the start of GnRHa and the start of chemotherapy for analysis: 1–6 days, 7–13 days, and ≥ 14 days. The ratio of the post-chemotherapy AMH value to the baseline AMH (pcAMH) at each time point were compared among the 3 groups. Ranked analysis of covariance was used for statistical analysis, adjusted for age, body mass index (BMI), and the existence of polycystic ovaries (PCOs). In addition, recovery of ovarian function (AMH ≥ 1 ng/mL) at 12 months was evaluated.
Results
The median age of the patients was 32 years. There was no difference in the baseline AMH levels among the 3 groups (mean ± standard error: 5.0 ± 0.4 ng/mL [1–6 days], 5.3 ± 0.7 ng/mL [7–13 days], and 8.1 ± 1.3 ng/mL [≥ 14 days]; p = 0.250). The pcAMH at 3, 6, 12, 24, and 36 months were not significantly different among the 3 groups (p-values were 0.332, 0.732, 0.830, 0.148, and 0.393, respectively). In multivariate analysis, young age (p = 0.024), low BMI (p = 0.013), and the existence of PCO (p = 0.015) were predictors for AMH ≥ 1 ng/mL at 12 months.
Conclusion
There was no difference in the ovarian protective effect according to the difference in the timing of administration of GnRHa.

Keyword

Breast neoplasms; Drug therapy; Fertility preservation; Gonadotropin-releasing hormone